Supplementary Material For: Immunotherapy-Induced Scarring Alopecia: A Case Series

This case series investigates scarring alopecia in patients treated with immune checkpoint inhibitors (ICI) for metastatic melanoma. Out of 450 patients, six developed scarring alopecia, indicating a prevalence of 1.33%. The study describes four cases, all involving female patients with a mean age of 64 years. Symptoms appeared on average 29.25 months after treatment initiation. Despite the alopecia, treatment was not discontinued, and all patients experienced favorable cancer outcomes. The study highlights the importance of understanding immune-induced alopecia to inform patients about potential psychological impacts and suggests further research into the link between treatment efficacy and follicular toxicity.